Enrico Cortesi

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest

Alfredo Falcone, Sergio Ricci, I. Brunetti et al. · Journal of Clinical Oncology · 2007 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Fotios Loupakis, Chiara Cremolini, Gianluca Masi et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Giovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti et al. · British Journal of Cancer · 2020 · 354 citations · Full text

Medicine, Immunology, Oncology +17

Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

Andrea Sartore‐Bianchi, Mauro Moroni, Silvio Veronese et al. · Journal of Clinical Oncology · 2007 · 337 citations · Full text

Medicine, Oncology, Pharmacology +17